glp-1 timeline of SGLT2i and GLP-1RA listed in the Australian Pharmaceutical What's next for GLP-1 innovation:

Patients should contact their healthcare provider if they experience persistent or severe dehydration symptoms, orthostatic dizziness, inability to keep fluids down, or very low urine output

Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death

All experiments involving rodents were performed under the protocol PACUC 1410001138 and experiments involving dogs were performed under the protocol PACUC 182001694

8 For patients, their total diabetes-related cost shareinclusive of medical and pharmacy costsdecreased by 50.5% since 2020

Cassano T, Pace L, Bedse G, Lavecchia AM, De Marco F, Gaetani S (2016) Glutamate and mitochondria: two prominent players in the oxidative stress-induced neurodegeneration